Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • ‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a while

‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a while

July 29, 2026Posted inBiotechnology

Biogen’s business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while.

Post navigation

Previous Post
optical-methods-tackle-complex-optimization-problems-faster-and-more-efficiently Optical methods tackle complex optimization problems faster and more efficiently
Next Post
Gene base editing reverses Huntington’s disease in mice gene-base-editing-reverses-huntington’s-disease-in-mice

Recent Posts

  • Activity-regulated myelin pathway drives organelle transport in oligodendrocytes
  • CD8⁺ TRM–chemokine axis drives liver fibrosis, reveals biomarkers in chronic Clonorchis infection
  • Paracetamol Use and Bronchopulmonary Dysplasia Risk in Extremely Preterm Infants
  • Community Partnership Measures Soil Lead in Urban Home Dust, Pre-/Post-1978
  • Global Markets React to New Shark Finning Regulations

Archives

  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top